Switch theme
Sign up to access all valuation multiples
Swedencare AB specializes in pet healthcare. It develops, manufactures partly in its factories, markets, and sells products in the fast-growing market of healthcare products for cats, dogs, and horses. The group has an extensive portfolio of brands and products in various therapy areas, including Animal Pharmaceuticals, Nutravet, NutriScience, Pet MD, Stratford, VetWELL, ProDen PlaqueOff, Rx Vitamins, Riley’s, NaturVet, Pet Organics, Overby Farm, Vet Classics, and Innovet’s brands. Its products are sold to veterinarians, pet stores, and online through a distribution network comprising various subsidiaries and an international network of retailers. The group's operating segments include North America, which generates maximum revenue, Europe, and Production.
2010
579
LTM Revenue $272M
LTM EBITDA $62.4M
$781M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Swedencare has a last 12-month revenue (LTM) of $272M and a last 12-month EBITDA of $62.4M.
In the most recent fiscal year, Swedencare achieved revenue of $262M and an EBITDA of $56.6M.
Swedencare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Swedencare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $272M | XXX | $262M | XXX | XXX | XXX |
| Gross Profit | $170M | XXX | $151M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $62.4M | XXX | $56.6M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $30.5M | XXX | $23.7M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $15.3M | XXX | $10.2M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $109M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Swedencare's stock price is SEK 40 (or $4).
Swedencare has current market cap of SEK 6.4B (or $655M), and EV of SEK 7.6B (or $781M).
See Swedencare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $781M | $655M | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Swedencare has market cap of $655M and EV of $781M.
Swedencare's trades at 3.0x EV/Revenue multiple, and 13.8x EV/EBITDA.
Equity research analysts estimate Swedencare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Swedencare has a P/E ratio of 42.8x.
See valuation multiples for Swedencare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $655M | XXX | $655M | XXX | XXX | XXX |
| EV (current) | $781M | XXX | $781M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.5x | XXX | 13.8x | XXX | XXX | XXX |
| EV/EBIT | 25.6x | XXX | 33.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.8x | XXX | 64.3x | XXX | XXX | XXX |
| EV/FCF | 42.0x | XXX | 26.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSwedencare's last 12 month revenue growth is 10%
Swedencare's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Swedencare's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Swedencare's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Swedencare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Swedencare acquired XXX companies to date.
Last acquisition by Swedencare was XXXXXXXX, XXXXX XXXXX XXXXXX . Swedencare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Swedencare founded? | Swedencare was founded in 2010. |
| Where is Swedencare headquartered? | Swedencare is headquartered in Sweden. |
| How many employees does Swedencare have? | As of today, Swedencare has 579 employees. |
| Who is the CEO of Swedencare? | Swedencare's CEO is Mr. Hakan Lagerberg. |
| Is Swedencare publicy listed? | Yes, Swedencare is a public company listed on STO. |
| What is the stock symbol of Swedencare? | Swedencare trades under SECARE ticker. |
| When did Swedencare go public? | Swedencare went public in 2016. |
| Who are competitors of Swedencare? | Similar companies to Swedencare include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Swedencare? | Swedencare's current market cap is $655M |
| What is the current revenue of Swedencare? | Swedencare's last 12 months revenue is $272M. |
| What is the current revenue growth of Swedencare? | Swedencare revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Swedencare? | Current revenue multiple of Swedencare is 2.9x. |
| Is Swedencare profitable? | Yes, Swedencare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Swedencare? | Swedencare's last 12 months EBITDA is $62.4M. |
| What is Swedencare's EBITDA margin? | Swedencare's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Swedencare? | Current EBITDA multiple of Swedencare is 12.5x. |
| What is the current FCF of Swedencare? | Swedencare's last 12 months FCF is $18.6M. |
| What is Swedencare's FCF margin? | Swedencare's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Swedencare? | Current FCF multiple of Swedencare is 42.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
